Same federal policy, different state answers

Federal enforcement discretion for six peptides sounds like a finish line. It isn't. State boards of pharmacy are now sorting through what the HHS policy means for pharmacies in their jurisdictions.

Utah has confirmed alignment. Arizona is considering its approach. Massachusetts has reminded pharmacies that USP standards and federal and state law still apply. Illinois is examining API sourcing, testing, safety data, and oversight. Different states, different questions, and potentially different answers.

Meanwhile, drugmakers are expected to push restrictive compounding legislation in statehouses across the country in 2027, with peptides joining GLP-1s as a target. Some boards of pharmacy may even support those proposals.